Skip Navigation


European Heart Journal Advance Access originally published online on August 3, 2006
European Heart Journal 2006 27(17):2031-2033; doi:10.1093/eurheartj/ehl157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/17/2031    most recent
ehl157v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cipollone, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cipollone, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Deoxyribonuclease I: exploring the hidden side of myocardial infarction

Francesco Cipollone

Centro Regionale per la Prevenzione dell'Aterosclerosi, Ce.S.I., University of Chieti ‘G.d'Annunzio’, ‘G.d'Annunzio’ University Foundation, via Colle dell'Ara, 66013 Chieti, Italy

Corresponding author. Tel: +39 0871 541360; fax: +39 0871 541491. E-mail address: fcipollone@unich.it

This editorial refers to ‘Association of Gln222Arg polymorphism in the deoxyribonuclease I (DNase I) gene with myocardial infarction in Japanese patients’{dagger} by T. Kumamoto et al., on page 2081

The first 150 words of the full text of this article appear below.

In the last years, the role of individual genetic background is contemplated in many aspects of medicine, such as receptiveness to diseases, disease evolution, and responses to drug treatment (pharmacogenomic).1

Genomes from different individuals are 99.9% identical, with only 0.1% of the genome showing mutations.2 Nevertheless, the rapid improvement in genome analysis has stimulated a colossal search for clinically relevant genomic polymorphisms, particularly single-nucleotide polymorphisms (SNPs), which consist of substitutions of one nucleotide for another in a DNA sequence.1 The possibility that SNPs may be useful in identifying candidate disease genes and individuals at risk of disease had led to extensive projects aimed at discovery and organization of SNPs into databases. At this time, about 2–3 million SNPs have been found in the human genome and are available in the public dbSNP databases,3 suggesting that if the promise of polymorphism analysis is realized, we are entering into an ‘era of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Association of Gln222Arg polymorphism in the deoxyribonuclease I (DNase I) gene with myocardial infarction in Japanese patients
Teruhiko Kumamoto, Yasuyuki Kawai, Kenichiro Arakawa, Norihiro Morikawa, Jun Kuribara, Hiroshi Tada, Koichi Taniguchi, Ryozo Tatami, Isamu Miyamori, Yoshihiko Kominato, Koichiro Kishi, and Toshihiro Yasuda
EHJ 2006 27: 2081-2087. [Abstract] [FREE Full Text]